Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments

• Type: Article in International Scientific Journal
• Date: 2023

Authors

Martins, RS (Author) Other; Jesus, TT (Author) Other; Cardoso, L (Author) Other; Soares, P (Author) FMUP; Vinagre, J (Author) Other

Journal

The Journal is awaiting validation by the Administrative Services.

Title: JOURNAL OF PERSONALIZED MEDICINE

Vol. 13

Final page: 1132

ISSN: 2075-4426

Publisher: MDPI

Indexing

ISI Web of Knowledge - 5 Citations

Scopus - 5 Citations

Other information

Authenticus ID: P-00Y-V1B

DOI: 10.3390/jpm13071132

Abstract (EN): Medullary thyroid carcinoma (MTC) arises from parafollicular cells in the thyroid gland, and although rare, it represents an aggressive type of thyroid cancer. MTC is recognized for its low mutational burden, with point mutations in RET or RAS genes being the most common oncogenic events. MTC can be resistant to cytotoxic chemotherapy, and multitarget kinase inhibitors (MKIs) have been considered a treatment option. They act by inhibiting the activities of specific tyrosine kinase receptors involved in tumor growth and angiogenesis. Several tyrosine kinase inhibitors are approved in the treatment of advanced MTC, including vandetanib and cabozantinib. However, due to the significant number of adverse events, debatable efficiency and resistance, there is a need for novel RET-specific TKIs. Newer RET-specific TKIs are expected to overcome previous limitations and improve patient outcomes. Herein, we aim to review MTC signaling pathways, the most recent options for treatment and the applications for personalized medicine.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 23